COZAAR Drug Patent Profile

Which patents cover Cozaar, and when can generic versions of Cozaar launch?

Cozaar is a drug marketed by Organon and is included in one NDA.

The generic ingredient in COZAAR is losartan potassium. There are thirty-nine drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the losartan potassium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cozaar

A generic version of COZAAR was approved as losartan potassium by AIPING PHARM INC on October 6^th, 2010.

Summary for COZAAR

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for COZAAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	COZAAR	losartan potassium	TABLET;ORAL	020386-001	Apr 14, 1995	AB	RX	Yes	No
Organon	COZAAR	losartan potassium	TABLET;ORAL	020386-002	Apr 14, 1995	AB	RX	Yes	No
Organon	COZAAR	losartan potassium	TABLET;ORAL	020386-003	Oct 13, 1998	AB	RX	Yes	Yes

International Patents for COZAAR

See the table below for patents covering COZAAR around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H0725738
Denmark	174948
Austria	146076

Supplementary Protection Certificates for COZAAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0253310	C950009	Netherlands		PRODUCT NAME: LOSARTAN, DESGEWENST IN DE VORM VAN EEN AANVAARDBAAR ZOUT, IN HET BIJZONDER HET KALIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 17617 19950314; FIRST REGISTRATION: SE 12209 19940902
0253310	96C0020	Belgium		PRODUCT NAME: KALII LOSARTAN; NAT. REGISTRATION NO/DATE: 922 IS 169 F3 19960130; FIRST REGISTRATION: SE 12209 19940902
0733366	98C0030	Belgium		PRODUCT NAME: KALII LOSARTAN, HYDROCHLOROTHIAZIDUM; NAT. REGISTRATION NO/DATE: 922 IS 174 F 3 19980223; FIRST REGISTRATION: FR 338 520.7 19950215

COZAAR Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Market Position and Financial Profile of COZAAR?

COZAAR (generic name: losartan) is an angiotensin II receptor blocker (ARB) primarily used to treat hypertension and reduce stroke risk. Originally marketed by Merck & Co., its patent expired in most markets by 2010, leading to a shift toward generic formulations. The drug's revenue trajectory now depends on generic competition, regulatory status, and evolving therapeutic guidelines.

How Does COZAAR Fit Into the Global Antihypertensive Market?

The global antihypertensive drugs market was valued at approximately $32 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of roughly 5% through 2028. Losartan remains a relevant therapy due to its efficacy, safety profile, and cost advantages relative to newer agents.

Market Shares and Competition

Drug Class	Major Drugs	Market Share (2022)	Key Competitors
ARBs	Losartan	30%	Valsartan, Telmisartan, Olmesartan
ACE inhibitors	Enalapril, Lisinopril	25%	Ramipril, Perindopril
Calcium channel blockers	Amlodipine	20%	Diltiazem, Verapamil
Others	Diuretics, Beta-blockers	25%	-

Losartan’s current demand is mainly from established markets with high hypertension prevalence, such as the US, Europe, and Japan.

What Is the Impact of Generics and Patent Expiry on Revenue Streams?

Post-patent expiry, revenue drops significantly for COZAAR compared to its patent-protected period (2002–2010). Generics now constitute a large proportion of sales, with market saturation preventing price hikes.

Pricing Dynamics

• Original brand price (before patent expiry): Approx. $5–$7 per tablet.
• Generic prices (post-2010): Approx. $0.10–$0.50 per tablet.
• Average annual sales for COZAAR (2002–2010): $2.5 billion globally.
• Generic market share (2022): 90% within the ARB segment.

Implications

• Margins for manufacturers with patent protection are high during the patent period.
• Generics suppress prices and revenues, pressuring brand companies to diversify or develop new formulations.

Is There Potential for Reformulation or New Indications?

While COZAAR's primary indications are well established, incremental opportunities include:

• Prescription of losartan for diabetic nephropathy.
• Combination therapies with other antihypertensives.

There have been studies examining losartan’s role in preventing cardiovascular events beyond hypertension, but regulatory approvals for new indications are limited.

How Do Regulatory and Patent Landscapes Affect Investment Outlook?

The core patent on losartan expired in 2010 in the US and EU. Patent protections for specific formulations or combination therapies may still exist, but the fragmentation limits exclusivity.

Regulatory Considerations

• No new blockbuster approvals for COZAAR; recent approvals focus on novel compounds or combinations.
• Biosimilars are unlikely due to the nature of small molecules, but multiple generic manufacturers dominate.

Market Entry Barriers

• Low due to generic manufacturing; quality standards maintained by agencies such as FDA and EMA.
• Regulatory approval processes are straightforward post-patent expiry.

What Is the Outlook for R&D and Investment in the Class?

Innovation in treating hypertension has shifted toward newer drug classes (e.g., soluble guanylate cyclase stimulators) and personalized medicine approaches. Existing ARBs like losartan are off-patent with minimal R&D investment, making them less attractive for new product development.

Investment Focus

• Generic manufacturing and distribution.
• Developing combination drugs with patent-protected elements.
• Expanding access in emerging markets.

What Are the Risks and Opportunities?

Risks

• Market saturation leading to thin margins.
• Price erosion due to widespread generics.
• Limited pipeline for COZAAR-specific innovation.

Opportunities

• Entry into untapped markets with high hypertension prevalence.
• Positioning as a cost-effective therapy in value-based healthcare settings.
• Developing fixed-dose combinations that incorporate losartan.

Key Takeaways

• COZAAR’s patent expired in most markets by 2010; the drug now mostly competes via generics.
• Revenues have declined post-patent expiry but remain relevant in low-cost markets.
• The competitive landscape favors price competition; margins are constrained.
• Innovation opportunities are limited; focus on distribution, combination therapies, and access.
• Market dynamics favor manufacturers with low-cost production and broad distribution networks.

FAQs

1. Will COZAAR regain market share with new formulations?
Unlikely, as patent protections for losartan have expired. New formulations offer limited differentiation unless combined with innovative delivery systems.

2. Are biosimilars an option for COZAAR?
No, biosimilars apply to biologics, not small molecules like losartan. Generics dominate the market structure.

3. Is there growth potential in emerging markets?
Yes. Regions with high hypertension prevalence and less access to healthcare can sustain demand and lower prices.

4. What are the key factors affecting profitability for generic losartan makers?
Low manufacturing costs, high volume sales, and strong distribution channels are critical for profit margins.

5. Should investors focus on ARB segment or alternative therapies?
Investors should consider the mature status of losartan and evaluate emerging therapies showing superior efficacy or safety profiles for growth opportunities.

References

1. Market Research Future. "Global Antihypertensive Drugs Market Report," 2022.
2. U.S. Food and Drug Administration. "Approved Drugs," 2023.
3. IQVIA. "Pharmaceutical Market Analysis," 2022.
4. European Medicines Agency. "Losartan registration details," 2022.
5. Pharmaceutical Commerce. "Impact of Patent Expiry in the Hypertension Segment," 2021.